Multiple SclerosisInfo Center

Saving the Mind From MS
One of the frustrating symptoms of multiple sclerosis (MS) is cognitive decline. Many patients have trouble with concentration, judgment and memory. Researchers wanted to learn if a drug that's effective with early dementia may help MS patients.
MS Drug Reaffirms Effectiveness in Clinical Trial
Gilenya , a FDA-approved multiple sclerosis drug, had positive results in a late-stage clinical trial. The results may help ease safety concerns about the drug.
Gene Connects Vitamin D with MS
What causes multiple sclerosis? There's been a lot of speculation, but few definitive answers. Researchers now believe they've found a troublesome gene that may cause MS in some patients.
Making Gains in MS Drug Research
A new medication for multiple sclerosis just got one step closer to being available for use. Researchers have published data that they believe shows exactly how the drug works in the brain.
MS and Gray Matter
Multiple sclerosis manifests in a wide range of symptoms, from difficulty with balance to fatigue and vision problems. These problems all originate in the brain, but how?
What You Eat and Drink Affects Your MS
If you have multiple sclerosis, will drinking wine make the disease worse? How about smoking? Or eating fish? How do daily choices affect your condition?
Memory Tricks for MS Patients
Have you ever gone to the grocery store and forgotten an item you went there to get? A technique used to improve learning and memory in multiple sclerosis patients may help you, too.
Long-Term Benefits With MS Drug
Primary progressive multiple sclerosis (PPMS) has no established course of treatment. But follow up results from a drug trial provide a glimmer of hope for patients.
Multiple Sclerosis and Depression Mixture
Dealing with a debilitating disease is challenging on its own. Add depression on top of it, and the burden of disease is crippling. For many patients with MS, that's reality.
A New Treatment for MS?
A new drug for multiple sclerosis (MS) has shown promising results in clinical trials. The drug, called ocrelizumab, has a novel new target to treat the disease.